Inovio Pharmaceuticals Inc (NASDAQ:INO) Expected to Post Quarterly Sales of $2.72 Million

Wall Street analysts expect that Inovio Pharmaceuticals Inc (NASDAQ:INO) will post sales of $2.72 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with the highest sales estimate coming in at $3.22 million and the lowest estimate coming in at $2.45 million. Inovio Pharmaceuticals posted sales of $2.00 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 36%. The firm is expected to report its next earnings report on Thursday, November 14th.

On average, analysts expect that Inovio Pharmaceuticals will report full year sales of $15.84 million for the current year, with estimates ranging from $8.00 million to $31.07 million. For the next fiscal year, analysts forecast that the company will report sales of $19.39 million, with estimates ranging from $10.00 million to $38.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.02). Inovio Pharmaceuticals had a negative return on equity of 128.73% and a negative net margin of 1,560.70%. The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $4.69 million. During the same quarter last year, the firm earned ($0.07) EPS.

Several analysts have commented on INO shares. BidaskClub cut shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 1st. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Inovio Pharmaceuticals in a research report on Tuesday, June 11th. Piper Jaffray Companies dropped their target price on shares of Inovio Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, July 17th. Finally, Maxim Group reiterated a “buy” rating and set a $6.00 target price on shares of Inovio Pharmaceuticals in a research report on Sunday. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Inovio Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $7.35.

In related news, insider Laurent Humeau purchased 20,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was purchased at an average cost of $2.50 per share, with a total value of $50,000.00. Following the completion of the purchase, the insider now owns 45,833 shares in the company, valued at approximately $114,582.50. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jong Joseph Kim sold 2,129,553 shares of Inovio Pharmaceuticals stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $2.36, for a total transaction of $5,025,745.08. Following the completion of the sale, the chief executive officer now directly owns 1,911,055 shares of the company’s stock, valued at $4,510,089.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,745,905 shares of company stock valued at $6,621,223. Company insiders own 7.90% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its holdings in Inovio Pharmaceuticals by 41.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 737,962 shares of the biopharmaceutical company’s stock worth $2,952,000 after purchasing an additional 217,536 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Inovio Pharmaceuticals by 3.8% in the 4th quarter. Bank of New York Mellon Corp now owns 360,828 shares of the biopharmaceutical company’s stock worth $1,444,000 after buying an additional 13,303 shares in the last quarter. Geode Capital Management LLC grew its stake in Inovio Pharmaceuticals by 14.2% in the 4th quarter. Geode Capital Management LLC now owns 1,004,095 shares of the biopharmaceutical company’s stock worth $4,016,000 after buying an additional 124,966 shares in the last quarter. Northern Trust Corp grew its stake in Inovio Pharmaceuticals by 1.0% in the 4th quarter. Northern Trust Corp now owns 1,048,508 shares of the biopharmaceutical company’s stock worth $4,194,000 after buying an additional 10,768 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. grew its stake in Inovio Pharmaceuticals by 49.7% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 4,884,100 shares of the biopharmaceutical company’s stock worth $14,359,000 after buying an additional 1,621,581 shares in the last quarter. 51.72% of the stock is owned by hedge funds and other institutional investors.

Shares of Inovio Pharmaceuticals stock traded down $0.09 on Friday, hitting $2.19. 883,626 shares of the company’s stock traded hands, compared to its average volume of 1,117,008. The firm has a 50-day moving average price of $2.80. The company has a market cap of $234.70 million, a PE ratio of -2.09 and a beta of 2.03. Inovio Pharmaceuticals has a one year low of $2.15 and a one year high of $6.30. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 1.02.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

See Also: What is the Book Value of a Share?

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit